Sankyo Benicar Offers No Significant Advantage Over Other ARBs, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sankyo’s antihypertensive Benicar (olmesartan medoxomil) may not offer significant benefits over the other six approved angiotensin II receptor blockers, FDA said in review documents for the NDA.